胃肠安治疗大肠癌术后脾虚证的临床研究  

Clinical Study on "Wei Chang An" in Treating Postoperative Colorectal Carcinoma of Spleen Deficiency

作　　者：周浩[1] 沈克平[1] 

机构地区：[1]上海中医药大学附属龙华医院肿瘤五科,上海200032

出　　处：《上海中医药杂志》2009年第6期36-38,共3页Shanghai Journal of Traditional Chinese Medicine

摘　　要：目的观察胃肠安治疗大肠癌术后脾虚证的临床疗效及其对免疫功能的影响。方法将94例大肠癌根治术后脾虚证患者随机分为治疗组(48例)和对照组(46例),两组在常规化疗基础上分别予胃肠安和加减旋覆代赭汤治疗,治疗6个月。观察治疗前后脾虚证候积分、KPS积分及T细胞亚群、NK细胞的变化情况。结果治疗后治疗组的脾虚证候积分明显下降(P<0.05),对照组无明显改善(P>0.05)。两组治疗后KPS评分均显著提高(P<0.05),组间差异有统计学意义(P<0.05)。治疗后治疗组CD3、CD4水平均明显升高(P<0.05),对照组CD8、NK水平明显升高(P<0.05)、CD4/CD8降低(P<0.05);组间治疗后比较,CD3、CD4、CD8、CD4/CD8、NK差异均有统计学意义(P<0.05)。结论胃肠安可以改善大肠癌术后脾虚证候,改善患者体能状况,增强细胞免疫功能,提高生活质量。Objective To observe the clinical efficacy of “Wei Chang An” in the treatment of postoperative colorectal carcinoma of spleen deficiency and its effect on immune function. Methods Ninty-four subjects were randomized into two groups： treatment group in which 48 cases were treated with chemotherapy and “Wei Chang An”, and control group in which 46 cases were treated with chemotherapy and “Xuanfu Daizhe Decoction”. The scores of spleen deficiency syndrome, Karnofsky performance status （KPS）, the counts of T cell subset and natural killer cell were observed before and after treatments. Results After six-month treat- ments, the scores of spleen deficiency syndrome were reduced significantly in treatment group（ P 〈0.05 ） and insignificantly in control group（ P 〉0.05 ） ; the KPS was significantly increased in both groups（ P 〈0.05 ）, with a difference between the two groups （P 〈 0.05 ） ; the counts of CD3 and CD4 were significantly increased in treatment group（ P 〈0.05 ）, and the counts of CD8 and NK were significantly increased （ P 〈0.05 ）, CD4/CD8 reduced in control group（ P 〈0.05 ）. Threre were great differences in CD3, CD4, CDS, CD4/CD8 and NK between two groups（ P 〈0.05 ）. Conclusion “Wei Chang An” can improve spleen deficiency syndrome, enhance cellular immue function and quality of life in postoperative eolorectal carcinoma patients.

关 键 词：大肠癌 脾虚证 中西医结合疗法 胃肠安 KPS评分 T细胞亚群 NK细胞 

分 类 号：R735.34[医药卫生—肿瘤]